亚盛医药-B(06855.HK)今日盘中股价大跌9.46%,引发市场广泛关注。主要原因是公司公布拟发售732.5万股美国存托股份,每股发售价相当于约33.57港元,较前日收市价折让19.6%。
公司此次发售美国存托股份预计可净集资1.13亿至1.31亿美元(约8.79亿至10.16亿港元),主要用于三方面: 1.在中国寻求lisaftoclax用于治疗r/r CLL的新药申请批准及商业化上市,并推进其在美国及其他国家的临床开发; 2.推进奥雷巴替尼在多国家的注册临床试验和上市工作; 3.资助其他候选产品如APG5918治疗贫血症的临床试验。
此次发售折让19.6%的存托股份为公司融资,虽然可以支持公司研发和商业化进程,但也存在摊薄现有股东持股比例的风险,因此引发股价大幅下跌。公司认为,发行美国存托股份并在纳斯达克全球市场上市,有利于接触更广泛的投资者群体和发展市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.